Urinary liver type fatty acid binding protein in diabetic nephropathy

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 104-108

  Kamijo Ikemori, Atsuko ^a   Sugaya, Takeshi ^a   Ichikawa, Daisuke ^a   Hoshino, Seiko ^a   Matsui, Katsuomi ^a   Yokoyama, Takeshi ^a   Yasuda, Takashi ^a   Hirata, Kazuaki ^a   Kimura, Kenjiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetic nephropathy; Tubulointerstitial damage; Urinary liver type fatty acid binding protein (L FABP)

Indexed keywords

ALISKIREN; AMLODIPINE; ANTIDIABETIC AGENT; AZELNIDIPINE; CANDESARTAN; FATTY ACID BINDING PROTEIN; GLIBENCLAMIDE; LISINOPRIL; LIVER TYPE FATTY ACID BINDING PROTEIN; LOSARTAN; NATEGLINIDE; OLMESARTAN; PIOGLITAZONE; PITAVASTATIN; ROSUVASTATIN; SPIRONOLACTONE; TELMISARTAN; TOXIN; UNCLASSIFIED DRUG; VOGLIBOSE;

ANEMIA; BIOLOGICAL MONITORING; CROSS-SECTIONAL STUDY; CYTOPLASM; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; ELISA KIT; EXPERIMENTAL STUDY; FOLLOW UP; GENE; GENE EXPRESSION REGULATION; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTERVENTION STUDY; KIDNEY INTERSTITIUM; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DISORDER; L FABP GENE; MACROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RENAL PROTECTION; REVIEW; URINARY EXCRETION; URODYNAMICS;

DIABETIC NEPHROPATHY; TUBULOINTERSTITIAL DAMAGE; URINARY LIVER-TYPE FATTY-ACID BINDING PROTEIN (L-FABP);

BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; JAPAN; KIDNEY TUBULES, PROXIMAL; SENSITIVITY AND SPECIFICITY;

EID: 84879594708     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.05.020     Document Type: Review

References (36)

1. Nath K.A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992, 20:1-17.
2. Sweetser D.A., Heuckeroth R.O., Gordon J.I. The metabolic significance of mammalian fatty-acid-binding proteins: abundant proteins in search of a function. Annu Rev Nutr 1987, 7:337-359.
3. Kamijo A., Sugaya T., Hikawa A., et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004, 165:1243-1255.
4. Yamamoto T., Noiri E., Ono Y., et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007, 18:2894-2902.
5. Kamijo-Ikemori A., Sugaya T., Obama A., et al. Liver type fatty acid binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am J Pathol 2006, 169:1107-1117.
6. Kamijo-Ikemori A., Sugaya T., Sekizuka A., et al. Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice. Nephrol Dial Transplant 2009, 24:788-800.
7. Matsui K., Kamijo-Ikemorif A., Sugaya T., et al. Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. Am J Pathol 2011, 178:1021-1032.
8. Yokoyama T., Kamijo-Ikemori A., Sugaya T., et al. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 2009, 174:2096-2106.
9. Ichikawa D., Kamijo-Ikemori A., Sugaya T., et al. Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury. Hypertension 2012, 60:973-980.
10. Kamijo A., Kimura K., Sugaya T., et al. Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease. J Lab Clin Med 2004, 143:23-30.
11. Kamijo-Ikemori A., Sugaya T., Yasuda T., et al. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011, 34:691-696.
12. Nakamura T., Sugaya T., Kawagoe Y., et al. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005, 28:2728-2732.
13. Nielsen S.E., Sugaya T., Tarnow L., et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009, 32:1684-1688.
14. Panduru N., Forsblom C., Saraheimo M., et al. Urinary Liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013, [in press].
15. Suzuki K., Babazono T., Murata H., Iwamoto Y. Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy. Diabetes Care 2005, 28:2038-2039.
16. Araki S., Haneda M., Koya D., et al. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 2013, 36:1248-1253.
17. Nielsen S.E., Sugaya T., Hovind P., et al. Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010, 33:1320-1324.
18. Abe M., Maruyama N., Okada K., et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011, 18:1018-1028.
19. Abe M., Maruyama N., Okada K., et al. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res 2011, 34:935-941.
20. Abe M., Maruyama N., Suzuki H., et al. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria. Hypertens Res 2012, 35:874-881.
21. Nakamura T., Fujiwara N., Sato E., et al. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy. Kidney Blood Press Res 2010, 33:213-220.
22. Nakamura T., Inoue T., Fujiwara N., et al. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Clin Nephrol 2008, 70:385-392.
23. Nakamura T., Sugaya T., Kawagoe Y., et al. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev 2006, 22:385-389.
24. Nielsen S.E., Persson F., Frandsen E., et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 2012, 29:e184-e190.
25. Kamijo-Ikemori A., Sugaya T., Matsui K., et al. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology (Carlton) 2011, 16:539-544.
26. Sasaki H., Kamijo-Ikemori A., Sugaya T., et al. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract 2009, 112:c148-c156.
27. Singh D.K., Winocour P., Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008, 4:216-226.
28. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006, 17:17-25.
29. Al-Khoury S., Afzali B., Shah N., et al. Anaemia in diabetic patients with chronic kidney disease-prevalence and predictors. Diabetologia 2006, 49:1183-1189.
30. Babazono T., Hanai K., Suzuki K., et al. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia 2006, 49:1387-1393.
31. Thomas M.C., Tsalamandris C., MacIsaac R.J., Jerums G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis 2006, 48:537-545.
32. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 38:955-962.
33. von Eynatten M., Baumann M., Heemann U., et al. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 2010, 40:95-102.
34. Ichimura T., Bonventre J.V., Bailly V., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998, 273:4135-4142.
35. Nakamura T., Sugaya T., Kawagoe Y., et al. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia. Am J Nephrol 2006, 26:276-280.
36. Nielsen S.E., Andersen S., Zdunek D., et al. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011, 79:1113-1118.